Navigation Links
New Generation Biofuels CEO to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/7/2008

condition and are based largely on our current beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward-looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.

CONTACT:

David Gillespie, President & CEO

New Generation Biofuels, Inc.

713-973-5720

Rob Schatz

Wolfe Axelrod Weinberger Associates, LLC

212-370-4500


'/>"/>
SOURCE New Generation Biofuels Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
2. Osteotech Receives FDA Clearance for its Next Generation Grafting Material
3. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
4. Spring Point Project Welcomes Second Generation Medical-Grade Piglets
5. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
6. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
7. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
8. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
9. Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology
10. Introducing the next generation of chemical reactors
11. First Coast Oncology to Offer Next Generation Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... and YONGIN, South Korea ... great pride that Green Cross Biotherapeutics Inc. (GCBT) kicked ... be located on the Montreal Technoparc,s Saint-Laurent Campus. The ... field investment projects in Canada ... of the first intravenous immunoglobulin (IVIG) and albumin manufacturing ...
(Date:6/1/2015)... , June 1, 2015 ... Decipher® genomic analysis platform, successfully classified various ... genomic expression of certain biomarkers, including one ... Importantly, this unique genomic signature has potential ... to neoadjuvant chemotherapy in patients with muscle-invasive ...
(Date:6/1/2015)... Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for ... first quarter financial statements and MD&A have been filed on SEDAR ... 31,(in CDN$,000 except per share data) , 2015 , ... profit , 1,531 , 329 Ebitda* , ... , (531) Basic earnings (loss) per share ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... in reconstructive and aesthetic plastic surgeryMEDFORD, Mass., ... growth-stage medical device company developing silk-based biomaterial ... has received 510(k) clearance from the U.S. ... SeriScaffold (TM) silk-based, long term bioresorbable ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... the National Institute of Allergy and Infectious Diseases ... in Maryland, USA. The research collaboration involves formulating ... and exploring potential vaccines for HIV and malaria. ...
... its financial results for the year ending 31,December 2008. , , ... process for intravenous iclaprim in US, - Restructuring ... "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of CHF ...
Cached Biology Technology:Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Genetic disease risk differences between one individual and another are ... the genes themselves, or else differences at the heart of ... By gene regulation we mean the decision that the cell ... activate or suppress the expression of a gene. In theory, ...
... those with HIV have recognized a relationship between how faithfully ... virus is to develop drug resistance. More recently, research has ... and resistance is different for each of the drugs that ... New research conducted by Harvard scientists could help explain ...
... ARBOR, Mich. Scientists have restored the sense of smell ... a hopeful sign for people who can,t smell anything from ... in curing congenital anosmia -- the medical term for lifelong ... other conditions that also stem from problems with the cilia. ...
Cached Biology News:A new light shed on genetic regulation's role in the predisposition to common diseases 2Design help for drug cocktails 2Design help for drug cocktails 3Can't smell anything? This discovery may give you hope 2Can't smell anything? This discovery may give you hope 3
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: